Amyris and ImmunityBio complete deal to develop COVID-19 vaccine, shares rise

Amyris

03/01/2022 13:43

** Shares of biotechnology firm  AMRS.O  up ~2% at $5.51 and
immunotherapy co  IBRX.O  up ~1% at $6.14, premarket 
    ** AMRS and partner IBRX announce completion of joint
venture agreement to accelerate the commercialization of a
next-generation COVID-19 vaccine  urn:newsml:reuters.com:*:nPn2FLnJva 
    ** AMRS initiated joint venture arrangement with IBRX in
November last year  urn:newsml:reuters.com:*:nL4N2RZ362 
    ** The vaccine has "a real opportunity to provide true
immunity against COVID-19 variants along with a platform that
can quickly adapt to a future potential respiratory virus", said
Patrick Soon-Shiong Global Chief Medical and Scientific Officer
of IBRX
    ** The companies expect to complete human trials and start
vaccine delivery this year 
    

 (Reporting by Oishee Majumdar in Bengaluru)
 ((oishee.majumdar@thomsonreuters.com;))